Standard techniques of drug discovery (high throughput screening, whole genome RNA interference, structure-based drug design, and animal models) have identified chemical modulators of RGS proteins (regulators of G protein signaling) with potential in neuropsychiatric disorders such as depression, pain, epilepsy, and Parkinson???s disease.